Company Description
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients.
The company’s clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor α1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases.
It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan.
The company was founded in 2010 and is headquartered in Singapore.
| Country | Singapore |
| Founded | 2010 |
| IPO Date | May 4, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 35 |
| CEO | Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. |
Contact Details
Address: 83 Clemenceau Avenue, #12-03 Ue Square Singapore, U0 239920 Singapore | |
| Phone | 65 6222 4235 |
| Website | aslanpharma.com |
Stock Details
| Ticker Symbol | ASLN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001722926 |
| CUSIP Number | 04522R101 |
| ISIN Number | US04522R2004 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. | Founder, Chief Executive Officer and Executive Director |
| Kiran Kumar Asarpota | Chief Operating Officer and Head of Finance |
| Ben Goodger | General Counsel |
| Stephen Doyle | Chief Business Officer |
| Dr. Alexandre Kaoukhov M.D. | Chief Medical Officer |
| Charlie Hsu | Investor Relations Director |
| Chi-Chin Wang | IR and Corporate Development Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2024 | 6-K | Report of foreign issuer |
| Jul 15, 2024 | 6-K | Report of foreign issuer |
| Jun 21, 2024 | EFFECT | Notice of Effectiveness |
| Jun 14, 2024 | 6-K | Report of foreign issuer |
| Jun 14, 2024 | F-6 POS | Post-effective amendments for immediately effective filing |
| Jun 12, 2024 | F-3 | Filing |
| May 31, 2024 | 6-K | Report of foreign issuer |
| May 9, 2024 | 6-K | Report of foreign issuer |
| May 7, 2024 | 6-K | Report of foreign issuer |
| Apr 22, 2024 | 6-K | Report of foreign issuer |